YY/T 1946-2024 English PDF

US$599.00 · In stock
Delivery: <= 5 days. True-PDF full-copy in English will be manually translated and delivered via email.
YY/T 1946-2024: Gene mutation in tumor tissue detection kit (high-throughput sequencing)
Status: Valid

Standard ID	USD	BUY PDF	Lead-Days	Standard Title (Description)	Status
YY/T 1946-2024	599	Add to Cart	5 days	Gene mutation in tumor tissue detection kit (high-throughput sequencing)	Valid

Similar standards

YY/T 1713   YY/T 1709   YY/T 1721   YY/T 1200   YY/T 1183   

Basic data

Standard ID: YY/T 1946-2024 (YY/T1946-2024)
Description (Translated English): Gene mutation in tumor tissue detection kit (high-throughput sequencing)
Sector / Industry: Medical Device & Pharmaceutical Industry Standard (Recommended)
Classification of Chinese Standard: C44
Classification of International Standard: 11.100.10
Word Count Estimation: 30,363
Date of Issue: 2024-09-29
Date of Implementation: 2025-10-15
Issuing agency(ies): State Drug Administration
Summary: This standard specifies the terms and definitions of the tumor tissue gene mutation detection kit (high-throughput sequencing method) (hereinafter referred to as the "kit"), specifies the relevant requirements, labels and instructions for use, as well as packaging, transportation and storage, and specifies the corresponding test methods. This standard is applicable to kits using high-throughput sequencing based on probe capture method or multiple PCR method.

YY/T 1946-2024: Gene mutation in tumor tissue detection kit (high-throughput sequencing)

---This is a DRAFT version for illustration, not a final translation. Full copy of true-PDF in English version (including equations, symbols, images, flow-chart, tables, and figures etc.) will be manually/carefully translated upon your order.
Pharmaceutical Industry Standards of the People's Republic of China ICS 11.100.10CCS C 44 Tumor tissue gene mutation detection kit (High-throughput sequencing) Gene mutation in tumor tissue detection kit (high⁃throughput sequencing) 2024-09-29 Release 2025-10-15 Implementation The State Drug Administration issued

Table of Contents

Preface Ⅲ Introduction Ⅳ 1 Scope...1 2 Normative references ...1 3 Terms and Definitions 1 4 Abbreviations 2 5 Requirements and test methods 3 6 Labels and instructions for use 7 7 Packaging, transportation and storage...7 Appendix A (Informative) National reference for the second generation of EGFR/ALK/MET gene mutation detection 8 Appendix B (Informative) Second-generation national reference for KRAS/NRAS/BRAF/PIK3CA gene mutation detection 13 Appendix C (Informative) National References for Tumor Mutation Burden 16 Appendix D (Informative) National Reference Materials for Microsatellite Instability (MSI) Detection 19 Appendix E (Informative) Key points to note during the test 22 Appendix F (Informative) Research on positive judgment value and performance evaluation method in kit design and development 23 References ...25

Foreword

This document is in accordance with the provisions of GB/T 1.1-2020 "Guidelines for standardization work Part 1.Structure and drafting rules for standardization documents" Drafting is required. Please note that some of the contents of this document may involve patents. The issuing organization of this document does not assume the responsibility for identifying patents. This document is proposed by the State Food and Drug Administration. This document is under the jurisdiction of the Medical High-throughput Sequencing Standardization Technology Management Unit. This document was drafted by. Beijing Jiyinga Medical Testing Laboratory Co., Ltd., China Food and Drug Inspection Institute, Beijing Medical Devices Medical Equipment Inspection Institute (Beijing Medical Biological Protection Equipment Inspection and Research Center), Peking Union Medical College Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Affiliated Cancer Hospital of Nanjing University, Nanjing Shihe Gene Biotechnology Co., Ltd., Zhenyue Biotechnology Jiangsu Co., Ltd., Xiamen Feishuo Biotechnology Biotechnology Co., Ltd., Shanghai Sildi Biomedical Technology Co., Ltd., and Beijing Youxun Medical Equipment Co., Ltd. The main drafters of this document are. Yi Xin, Jia Zheng, Wang Ruixia, Liang Zhiyong, Ying Jianming, Zhou Xiaoyan, Shao Yang, Zheng Shan, Chen Yan, Guan Li, Shan Guangyu, Yi Yuting, Chu Yuxing, Yuan Fuqiang, Yu Ting, Qu Shoufang, Huang Jie.

Introduction

The tumor tissue gene mutation detection kit (high-throughput sequencing method) in this document refers to a method for converting nucleic acid fragments into a sequenceable library. The kit mainly comprises deoxyribonucleoside triphosphates, ligase, polymerase, linker, primers, probes and the like. It is important to emphasize that an IVD test system is a combination of components that complete all stages from sample processing to final result reporting. For example, the tumor tissue gene mutation detection (high-throughput sequencing) detection system includes not only the kits referred to in this document, but also nucleic acid When designing, developing and verifying extraction kits, gene sequencers, sequencing reagents, data analysis software, etc., complete and definite The detection system is analyzed and the performance is evaluated to complete the evaluation of each part of the detection system. In the process of clinical application, with the development of technology and the deepening of clinical research, there are more and more database construction methods, data analysis software, databases, etc. We suggest that developers take the initiative to update the products on the market based on their in-depth understanding of product design, production process and quality control. Continuous improvement and innovation of products. According to the relevant requirements of in vitro diagnostic reagent production quality management, when the above changes may affect product safety When evaluating the risks that may be caused by the changes, and taking measures to reduce the risks to an acceptable level when necessary, the relevant Regulatory requirements. This document is based on the application and validation data of high-throughput sequencing technology and is intended for manufacturers of in vitro diagnostic reagents and medical testing laboratories. etc. for use. Tumor tissue gene mutation detection kit (High-throughput sequencing)

1 Scope

This document defines the terms and definitions of the tumor tissue gene mutation detection kit (high-throughput sequencing method) (hereinafter referred to as the "kit"). It specifies relevant requirements, labels and instructions for use as well as packaging, transportation and storage, and describes the corresponding test methods. This document applies to kits that use high-throughput sequencing based on probe capture or multiplex PCR for the detection of tumors. Single nucleotide variants (SNVs), insertion/deletion variants (Indels), Copy number variations (CNAs), gene fusions, tumor mutation burden (TMB), and/or microsatellite instability (MSI). The kit is also suitable for paired detection of tumor tissue and control samples. This document does not apply to kits that use whole exome sequencing and single molecule sequencing technology to detect tumor gene mutations. Note. The control sample may be whole blood or adjacent tissue sample, which is mainly used to distinguish germline mutations in tumor FFPE tissue sample testing.

2 Normative references

The contents of the following documents constitute the essential clauses of this document through normative references in this document. For referenced documents without a date, only the version corresponding to that date applies to this document; for referenced documents without a date, the latest version (including all amendments) applies to This document. GB/T 191 Pictorial markings for packaging, storage and transportation GB/T 29791.2 Information provided by the manufacturer of in vitro diagnostic medical devices (labeling) Part 2.Professional in vitro diagnostic reagents

3 Terms and definitions

The following terms and definitions apply to this document. 3.1 High-throughput sequencing Different from traditional dideoxy (Sanger) sequencing, a technology that can perform parallel sequencing of a large number of nucleic acid molecules at one time, Usually one sequencing reaction can produce no less than 100Mb of sequencing data. [Source. GB/T 40664-2021, 3.8] 3.2 Single-nucleotide variants; SNVs A type of variation caused by the substitution of a single nucleotide base at the same position in the genome. 3.3 Insertion and deletion alterations; Indels A type of variation that occurs when one or more bases are inserted or deleted in the genome. Note. Usually refers to 1 to 50 bases. ......

Image     

Tips & Frequently Asked Questions:

Question 1: How long will the true-PDF of YY/T 1946-2024_English be delivered?

Answer: Upon your order, we will start to translate YY/T 1946-2024_English as soon as possible, and keep you informed of the progress. The lead time is typically 3 ~ 5 working days. The lengthier the document the longer the lead time.

Question 2: Can I share the purchased PDF of YY/T 1946-2024_English with my colleagues?

Answer: Yes. The purchased PDF of YY/T 1946-2024_English will be deemed to be sold to your employer/organization who actually pays for it, including your colleagues and your employer's intranet.

Question 3: Does the price include tax/VAT?

Answer: Yes. Our tax invoice, downloaded/delivered in 9 seconds, includes all tax/VAT and complies with 100+ countries' tax regulations (tax exempted in 100+ countries) -- See Avoidance of Double Taxation Agreements (DTAs): List of DTAs signed between Singapore and 100+ countries

Question 4: Do you accept my currency other than USD?

Answer: Yes. If you need your currency to be printed on the invoice, please write an email to Sales@ChineseStandard.net. In 2 working-hours, we will create a special link for you to pay in any currencies. Otherwise, follow the normal steps: Add to Cart -- Checkout -- Select your currency to pay.